Royalty Pharma plc (RPRX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は New York City, NY, アメリカ. 現CEOは Pablo Legorreta.
RPRX を有する IPO日 2020-06-16, 75 名の正社員, に上場 NASDAQ Global Select, 時価総額 $20.92B.
Royalty Pharma plc is a biopharmaceutical royalty company that identifies, evaluates, and acquires royalty streams from innovative drug therapies across the United States. The company collaborates with academic institutions, research hospitals, biotechnology companies, and pharmaceutical firms to fund biopharmaceutical innovation. Its diversified portfolio includes royalties on approximately 35 marketed therapies and 10 development-stage product candidates spanning therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. Founded in 1996 and headquartered in New York, Royalty Pharma generates revenue through its ownership of royalty interests in marketed drugs while supporting the advancement of new treatments.